Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Franke

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
IJTLD Open|May 14, 2025
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TBC Zeng, M A Hernán, L Trevisi, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosisChengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed DrugsIsmat Lotia Farrukh, Nathalie Lachenal, Malik M Adenov, et al.
The European Respiratory Journal|June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settingsPalwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCatherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine|February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant TuberculosisLetizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Plos One|March 22, 2013
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCarole D Mitnick, Molly F Franke, Michael L Rich, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
The New England Journal of Medicine|August 9, 2008
Comprehensive treatment of extensively drug-resistant tuberculosisCarole D Mitnick, Sonya S Shin, Kwonjune J Seung, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
IJTLD Open|May 14, 2025
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TBC Zeng, M A Hernán, L Trevisi, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosisChengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed DrugsIsmat Lotia Farrukh, Nathalie Lachenal, Malik M Adenov, et al.
The European Respiratory Journal|June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settingsPalwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCatherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine|February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant TuberculosisLetizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Plos One|March 22, 2013
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCarole D Mitnick, Molly F Franke, Michael L Rich, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
The New England Journal of Medicine|August 9, 2008
Comprehensive treatment of extensively drug-resistant tuberculosisCarole D Mitnick, Sonya S Shin, Kwonjune J Seung, et al.
Pageof 26